Clinical Benefit, Price, and Regulatory Approval of Cancer Drugs Granted Breakthrough Therapy Designation in China, 2020-2024
The findings of this cross-sectional study suggest that BTD has facilitated faster time to market for cancer drugs and improved novelty, but the price of treatment is relatively higher. There was no significant difference on comparative efficacy and safety.
Authors
- Xingxian Luo
- Yue Yang (ORCID: https://orcid.org/0000-0003-1015-8998)
- Xufeng Lv
- Xiaohong Zhang (ORCID: https://orcid.org/0000-0002-6732-2499)
- Xin Du (ORCID: https://orcid.org/0000-0002-8779-5955)
- Lin Huang (ORCID: https://orcid.org/0000-0002-4899-9621)
Institutions
- Peking University (CN)
- National Medical Products Administration (CN)
- Peking University People's Hospital (CN)
- Vanke (China) (CN)
- Tsinghua University (CN)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2024-10-16
- DOI
- https://doi.org/10.1001/jamanetworkopen.2024.39080
- Citations
- 6
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 6.78
Funders
- National Natural Science Foundation of China